Literature DB >> 1376368

Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.

B K Sil1, L M Dunster, T N Ledger, M R Wills, P D Minor, A D Barrett.   

Abstract

Monoclonal antibodies (MAbs) have been prepared against vaccine and wild-type strains of yellow fever (YF) virus, and envelope protein epitopes specific for vaccine (MAbs H5 and H6) and wild-type (MAbs S17, S18, S24, and S56) strains of YF virus have been identified. Wild-type YF virus FVV, Dakar 1279, and B4.1 were each given six passages in HeLa cells. FVV and B4.1 were attenuated for newborn mice following passage in HeLa cells, whereas Dakar 1279 was not. Examination of the envelope proteins of the viruses with 87 MAbs showed that attenuated viruses gained only the vaccine epitope recognized by MAb H5 and lost wild-type epitopes recognized by MAbs S17, S18, and S24 whereas the nonattenuated Dakar 1279 HeLa p6 virus did not gain the vaccine epitope, retained the wild-type epitopes, and showed no other physical epitope alterations. MAb neutralization-resistant (MAbr) escape variants generated by using wild-type-specific MAbs S18 and S24 were found to lose the epitopes recognized by MAbs S18 and S24 and to acquire the epitope recognized by vaccine-specific MAb H5. In addition, the MAbr variants became attenuated for mice. Thus, the data presented in this paper indicate that acquisition of vaccine epitopes and loss of wild-type epitopes on the envelope protein are directly involved in the attenuation process of YF virus and suggest that the envelope protein is one of the genes encoding determinants of YF virus pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376368      PMCID: PMC241231     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  UTILIZATION OF DISPOSABLE PLASTIC PLATES, WITH A SEROLOGIC MICROTECHNIC.

Authors:  J L SEVER; A C LEY; F WOLMAN; B M CAPLAN; P W CROCKETT; H C TURNER
Journal:  Am J Clin Pathol       Date:  1964-02       Impact factor: 2.493

2.  Attenuation of wild-type yellow fever virus by passage in HeLa cells.

Authors:  A D Barrett; T P Monath; C B Cropp; J A Adkins; T N Ledger; E A Gould; J J Schlesinger; R M Kinney; D W Trent
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

3.  Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus.

Authors:  A D Barrett; J H Mathews; B R Miller; A R Medlen; T N Ledger; J T Roehrig
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

4.  Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies.

Authors:  E A Gould; A Buckley; N Cammack; A D Barrett; J C Clegg; R Ishak; M G Varma
Journal:  J Gen Virol       Date:  1985-07       Impact factor: 3.891

5.  Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools.

Authors:  E A Gould; A Buckley; P A Cane; S Higgs; N Cammack
Journal:  J Gen Virol       Date:  1989-07       Impact factor: 3.891

6.  Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.

Authors:  C S Hahn; J M Dalrymple; J H Strauss; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.

Authors:  J J Schlesinger; M W Brandriss; T P Monath
Journal:  Virology       Date:  1983-02       Impact factor: 3.616

8.  A continuing focus of yellow fever in the Apurimac River Valley, Ayacucho, Peru, and the first isolation of yellow fever virus in that country.

Authors:  M R Méndez; C H Calisher; H Kruger; F Sipan; S Sánchez; J S Lazuick
Journal:  Bull Pan Am Health Organ       Date:  1984

9.  Genetic variation of Japanese encephalitis virus in nature.

Authors:  W R Chen; R B Tesh; R Rico-Hesse
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

10.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more
  7 in total

1.  Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Authors:  Monica A McArthur; Miguel T Suderman; John-Paul Mutebi; Shu-Yuan Xiao; Alan D T Barrett
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing.

Authors:  Andrew Beck; Robert B Tesh; Thomas G Wood; Steven G Widen; Kate D Ryman; Alan D T Barrett
Journal:  J Infect Dis       Date:  2013-10-17       Impact factor: 5.226

Review 3.  Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.

Authors:  Florian Douam; Alexander Ploss
Journal:  Trends Microbiol       Date:  2018-06-19       Impact factor: 17.079

4.  Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses.

Authors:  Maria Dolores Fernandez-Garcia; Laurent Meertens; Maxime Chazal; Mohamed Lamine Hafirassou; Ophélie Dejarnac; Alessia Zamborlini; Philippe Despres; Nathalie Sauvonnet; Fernando Arenzana-Seisdedos; Nolwenn Jouvenet; Ali Amara
Journal:  MBio       Date:  2016-02-09       Impact factor: 7.867

5.  Molecular determinants of Yellow Fever Virus pathogenicity in Syrian Golden Hamsters: one mutation away from virulence.

Authors:  Raphaëlle Klitting; Laura Roth; Félix A Rey; Xavier de Lamballerie
Journal:  Emerg Microbes Infect       Date:  2018-03-29       Impact factor: 7.163

Review 6.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

Review 7.  Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises.

Authors:  Aoife K O'Connell; Florian Douam
Journal:  Vaccines (Basel)       Date:  2020-01-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.